2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

JNK cell

" in MedChemExpress (MCE) Product Catalog:

116

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

7

Peptides

1

Inhibitory Antibodies

34

Natural
Products

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10140
    JNK-IN-15, Cell-Permeable

    		JNK Cancer
    JNK-IN-15, Cell-Permeable (JNK inhibitor III) is an inhibitor of JNK. JNK-IN-15, Cell-Permeable can used in study age-related neurodegenerative diseasev .
    JNK-IN-15, Cell-Permeable
  • HY-P10141
    JNK-IN-15, Cell-Permeable, Negative Control

    		JNK Cancer
    JNK-IN-15, Cell-Permeable, Negative Control is a negative control of JNK-IN-15, Cell-Permeable (HY-P10140). JNK-IN-15, Cell-Permeable is an inhibitor of JNK .
    JNK-IN-15, Cell-Permeable, Negative Control
  • HY-163451
    Apoptosis inducer 17

    		Apoptosis Cancer
    Apoptosis inducer 17 is a Curcumin-Piperlongumine hybrid molecule that increases cell cycle arrest and apoptosis through activating JNK signaling pathway in lung cancer cells .
    Apoptosis inducer 17
  • HY-152774
    Antitumor agent-86

    		Akt PI3K Cancer
    Antitumor agent-86 (compound 5a) inhibits MCF-7 breast cancer cells with an IC50 value of 2.62 µM. Antitumor agent-86 induces cell apoptosis and cell cycle arrest, and shows antineoplastic activity by targeting RAS/PI3K/Akt/JNK signaling cascades .
    Antitumor agent-86
  • HY-146323
    Antitumor agent-58

    		Apoptosis Cancer
    Antitumor agent-58 (Compound C18) is an anti-tumor agent. Antitumor agent-58 effectively inhibits colony formation and cell migration of MGC-803 cells. Antitumor agent-58 induces apoptosis of MGC-803 cells through activation of the p38 and JNK signaling pathways. Antitumor agent-58 induces mitochondrial dysfunction of MGC-803 cells. Antitumor agent-58 effectively inhibits tumor growth of xenograft model bearing MGC-803 cells .
    Antitumor agent-58
  • HY-156182
    JNK-IN-14

    		JNK Cytochrome P450 Cancer
    JNK-IN-14 is a potent JNK inhibitor with IC50 values of 1.81, 12.7 and 10.5 nM for JNK1, JNK2 and JNK3, respectively. JNK-IN-14 induces early-stage apoptosis. JNK-IN-14 shows cell population arrest at the G2/M phase and slightly inhibits beclin-1 production at K562 leukemia cells relative to SP600125 (HY-12041), showing higher inhibitory ability.
    JNK-IN-14
  • HY-13319G
    JNK-IN-8

    JNK Inhibitor XVI

    		 JNK Cancer
    JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively .
    JNK-IN-8
  • HY-151962
    JNK3 inhibitor-5

    		JNK Apoptosis GSK-3 p38 MAPK Neurological Disease
    JNK3 inhibitor-5 (Compound 22b) is a potent and selective JNK3 inhibitor with an IC50 of 0.379 nM. JNK3 inhibitor-5 effectively protects the neuronal cells against amyloid beta-induced apoptosis. JNK3 inhibitor-5 has a high cell permeability and is predicted as BBB permeable .
    JNK3 inhibitor-5
  • HY-162332
    EGFR-PK/JNK-2-IN-1

    		Apoptosis EGFR JNK Cancer
    EGFR-PK/JNK-2-IN-1 (Compound 6c) is a dual inhibitor of EGFR-PK and JNK-2 with IC50s of 2.7 and 3.0 μM, respectively. EGFR-PK/JNK-2-IN-1 can induce apoptosis and induce cell cycle arrest at different cell phases. EGFR-PK/JNK-2-IN-1 can be used for the research of cancer .
    EGFR-PK/JNK-2-IN-1
  • HY-155077
    JNK-IN-12

    		JNK Cancer
    JNK-IN-12 (compound P2) is a mitochondrial-targeted JNK inhibitor (IC50=66.3 nM), consisting of a mitochondrial-specific cell-penetrating peptide and a specific inhibitor of JNK, SP600125 (HY-12041). JNK-IN-12 doesn't inhibit nuclear JNK signaling, but does inhibit mitochondrial JNK phosphorylation. JNK-IN-12 helps to improve the Parkinson's disease (PD) both in vitro and in vivo .
    JNK-IN-12
  • HY-12041
    SP600125
    Maximum Cited Publications
    517 Publications Verification

    		 JNK Autophagy Apoptosis Ferroptosis Cancer
    SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
    SP600125
  • HY-169021
    JNK-1-IN-3

    		JNK Cancer
    JNK-1-IN-3 (Compound 9e) is an inhibitor of JNK1 that downregulates JNK1 gene expression and inhibits the protein levels of its phosphorylated form, concurrently reducing the expression of its downstream targets, c-Jun and c-Fos, in tumors while restoring p53 activity. JNK-1-IN-3 exhibits broad-spectrum antiproliferative activity, particularly with high inhibitory activity against renal and breast cancer cell lines, demonstrating both in vivo and in vitro anticancer activity .
    JNK-1-IN-3
  • HY-120349
    LL-Z1640-4

    		p38 MAPK JNK Apoptosis Reactive Oxygen Species (ROS) Cancer
    LL-Z1640-4 is a potent p38/JNK signaling inhibitor. LL-Z1640-4 significantly diminishes p38 and JNK activation in HCC cells transfected with MLK4 siRNA. LL-Z1640-4 markedly attenuates ROS production induced by MLK4 knockdown. LL-Z1640-4 significantly reduces the apoptotic cells in HCC cells transfected with siMLK4 .
    LL-Z1640-4
  • HY-P0069A
    L-JNKI-1
    2 Publications Verification

    		 JNK Neurological Disease
    L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.
    L-JNKI-1
  • HY-12041R
    SP600125 (Standard)

    		JNK Autophagy Apoptosis Ferroptosis Cancer
    SP600125 (Standard) is the analytical standard of SP600125. This product is intended for research and analytical applications. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
    SP600125 (Standard)
  • HY-138304
    CC-90001
    1 Publications Verification

    		 JNK Inflammation/Immunology
    CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis .
    CC-90001
  • HY-173153
    BRAFV600E/JNK-IN-1

    		JNK PERK MEK NO Synthase Inflammation/Immunology Cancer
    BRAFV600E/JNK-IN-1 (Compound 14c) is an inhibitor of JNK1, JNK2, JNK3 and BRAFV600E, with IC50 values of 0.51 μM, 0.53 μM, 1.02 μM and 0.009 μM, respectively. BRAFV600E/JNK-IN-1 can inhibit the phosphorylation of MEK1/2 and ERK1/2. In addition, BRAFV600E/JNK-IN-1 can inhibit tumor cell proliferation, NO release and PGE2 production, and has anti-tumor and anti-inflammatory activities .
    BRAFV600E/JNK-IN-1
  • HY-12862
    Mps1-IN-7

    		Mps1 Cancer
    Mps1-IN-7 is a potent MPS1 inhibitor (IC50 of 0.020 μM) over JNK1 and JNK2 (JNK1 IC50= 0.11 μM, JNK2 IC50=0.22 μM). Mps1-IN-7 inhibit SW620, CAL51, Miapaca-2, RMG1 cell growth with GI50 values of 0.065, 0.068, 0.25, and 0.110 μM,respectively .
    Mps1-IN-7
  • HY-137135
    Cantharidic acid

    		Phosphatase Apoptosis ERK p38 MAPK JNK Cancer
    Cantharidic acid is a selective inhibitor for protein phosphatase 2 (PP2A) and protein phosphatase 1 (PP1). Cantharidic acid inhibits cell viability and arrest cell cycle at sub G1 phase, induces apoptosis in cells NPC-39 and HONE-1 through the upregulation of ERK1/2, p38, and JNK1/2 pathway .
    Cantharidic acid
  • HY-P0069
    D-JNKI-1
    5+ Cited Publications

    AM-111; XG-102

    		 JNK Others
    D-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK.
    D-JNKI-1
  • HY-N2149A
    Tomatidine hydrochloride
    5+ Cited Publications

    		 NF-κB JNK Autophagy Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling . Tomatidine hydrochloride activates autophagy either in mammal cells or C elegans .
    Tomatidine hydrochloride
  • HY-N2149
    Tomatidine
    5+ Cited Publications

    		 NF-κB JNK Autophagy Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Tomatidine acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling . Tomatidine activates autophagy either in mammal cells or C elegans .
    Tomatidine
  • HY-B1309
    Metacetamol

    AMAP

    		 JNK Reactive Oxygen Species (ROS) Metabolic Disease
    Metacetamol (AMAP) is a non-hepatotoxic analog of acetaminophen (APAP). Metacetamol increases glutathione (GSH) in PHH and causes mitochondrial damage. Metacetamol increases total JNK in PHH cell .
    Metacetamol
  • HY-101287
    MPT0B392

    		Microtubule/Tubulin JNK Apoptosis Caspase Cancer
    MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line .
    MPT0B392
  • HY-121605
    RL71

    		Apoptosis Cancer
    RL71 is a curcuminoid anticancer agent that exhibits potent cytotoxicity against a variety of ER-negative breast cancer cells. RL71 (1 μM) induces cell cycle arrest in the G2/M phase and induces apoptosis in SKBr3 cells. RL7 also decreases HER2/neu phosphorylation and increases p27. RL71 also significantly reduced the phosphorylation of Akt and transiently increased the stress kinases JNK1/2 and p38 MAPK. Furthermore, RL71 exhibited anti-angiogenic potential in vitro, inhibiting the migration of HUVEC cells and the ability of these cells to form tubular networks .
    RL71
  • HY-147513
    AKT-IN-12

    		Akt Apoptosis Cancer
    AKT-IN-12 (compound 3e) is a potent Akt kinase inhibitor with an IC50 value of 0.55 μM. AKT-IN-12 induces G0/G1 cell cycle arrest and apoptosis. AKT-IN-12 also inhibits p-AKT, p-ERK, and activates p-JNK, JNK. AKT-IN-12 can be used for researching leukemia .
    AKT-IN-12
  • HY-N3711
    Dehydrocrenatine

    		JNK ERK Apoptosis Neurological Disease
    Dehydrocrenatidine, a β-carboline alkaloid that can be isolated from Picrasma quassioides. Dehydrocrenatidine induces cell apoptosis by activates ERK and JNK. Dehydrocrenatidine inhibits invasion and migration of cancer cells, it also suppresses neuronal excitability to exert analgesic effects .
    Dehydrocrenatine
  • HY-P1190
    c-JUN peptide

    		JNK Apoptosis Inflammation/Immunology
    c-JUN peptide is a cell-permeable c-JUN-JNK interaction inhibitor. c-JUN peptide inhibits serum-induced c-Jun phosphorylation. c-JUN peptide induces apoptosis .
    c-JUN peptide
  • HY-N1961
    Ophiopogonin B

    OP-B

    		 JNK Apoptosis Cancer
    Ophiopogonin B (OP-B) induces the autophagy and apoptosis of colon cancer cells by activating JNK/c-Jun signaling pathway. Ophiopogonin B is a saponin compound isolated from Radix Ophiopogonjaponicus .
    Ophiopogonin B
  • HY-N6032
    Esculentoside B

    Phytolaccoside B

    		 Cholinesterase (ChE) JNK NF-κB Fungal Infection Neurological Disease Inflammation/Immunology
    Esculentoside B (Phytolaccoside B) is a natural product from the roots of Phytolacca acinosa Roxb. Esculentoside B is neurotoxic to zebrafish larvae, and impairs their central nervous system development. Esculentoside B inhibits inflammatory response and has antifungal activity .
    Esculentoside B
  • HY-N2205
    Esculentoside H
    1 Publications Verification

    		 NF-κB JNK Cancer
    Esculentoside H (EsH) is a saponin isolated from the root extract of perennial plant Phytolacca esculenta . Esculentoside H (EH) has anti-tumor activity, the mechanism is related to the capacity for TNFrelease . Esculentoside H (EsH) suppresses colon cancer cell migration through blockage of the JNK1/2 and NF-κB signaling-mediated matrix metalloproteinases-9 (MMP-9) expression .
    Esculentoside H
  • HY-N3442
    Juglanin
    5+ Cited Publications

    		 JNK Apoptosis Autophagy Inflammation/Immunology Cancer
    Juglanin, a occurring flavonoid that can be isolated from crude Polygonum aviculare, is a JNK acticator, with anti-inflammatory, anti-oxidant and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells .
    Juglanin
  • HY-122315
    Oncrasin-60

    NSC-741909

    		 JNK Apoptosis Cancer
    Oncrasin-60 (NSC-741909) is a compound with antitumor activity that is active against multiple cancer cell lines in vitro and can induce tumor regression in vivo, with its mechanism involving JNK activation and STAT3 inhibition.
    Oncrasin-60
  • HY-N13121
    Daphnegiravone D

    		HDAC Apoptosis p38 MAPK Cancer
    Daphnegiravone D (compound 70) is an HDAC6 inhibitor with anti-hepatocellular carcinoma activity. Daphnegiravone D can induce apoptosis and selectively inhibit the proliferation of liver cancer cells through the p38 and JNK MAPK pathways .
    Daphnegiravone D
  • HY-121683
    (E)-2-Hexadecenal

    trans-2-Hexadecenal

    		 Mixed Lineage Kinase Apoptosis JNK Microtubule/Tubulin Cancer
    (E)-2-Hexadecenal (trans-2-Hexadecenal) is an MLK3 activator that induces cytoskeletal remodeling, leading to cell rounding, detachment, and ultimately apoptosis in human and mouse cells. (E)-2-Hexadecenal activates the MLK3 signaling pathway, phosphorylating MKK4/7 and JNK, subsequently activating downstream targets of JNK, such as c-Jun phosphorylation, cytochrome c release, Bax activation, Bid cleavage, and Bim translocation to mitochondria. (E)-2-Hexadecenal has potential applications in research related to sphingolipid signaling pathways .
    (E)-2-Hexadecenal
  • HY-121605S
    RL71-d6

    		Isotope-Labeled Compounds Apoptosis Cancer
    RL71-d6 is a deuterium labeled RL71 (HY-121605). RL71 is a curcuminoid anticancer agent that exhibits potent cytotoxicity against a variety of ER-negative breast cancer cells. RL71 (1 μM) induces cell cycle arrest in the G2/M phase and induces apoptosis in SKBr3 cells. RL7 also decreases HER2/neu phosphorylation and increases p27. RL71 also significantly reduced the phosphorylation of Akt and transiently increased the stress kinases JNK1/2 and p38 MAPK. Furthermore, RL71 exhibited anti-angiogenic potential in vitro, inhibiting the migration of HUVEC cells and the ability of these cells to form tubular networks .
    RL71-d6
  • HY-10412
    CEP-1347

    KT7515

    		 JNK Mixed Lineage Kinase MDM-2/p53 Neurological Disease
    CEP-1347 is an inhibitor of the JNK/SAPK pathway with neuroprotective effects. CEP-1347 blocks JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase). As an inhibitor of MDM4, CEP-1347 can more effectively inhibit the growth of glioma cells expressing wild-type p53 .
    CEP-1347
  • HY-N6872
    Actein

    		JNK Akt Apoptosis Autophagy Reactive Oxygen Species (ROS) Cancer
    Actein, a triterpene glycoside, shows an inhibitory effect on cancer cells, which is isolated from the rhizomes of Cimicifuga foetida. Actein suppresses cell proliferation, induces autophagy and apoptosis through promoting ROS/JNK activation, and blunting AKT pathway in bladder cancer. Actein has little toxicity in vivo .
    Actein
  • HY-N0431
    Astragaloside IV
    20+ Cited Publications

    		 MMP ERK JNK Cancer
    Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
    Astragaloside IV
  • HY-W011398
    Linoleate sodium

    		Interleukin Related JNK NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Linoleate sodium is an orally active IL8 regulator via the JNK and NF-κB pathway. Linoleate sodium can change the composition of fatty acids and the production of metabolites in cells. Linoleate sodium has anti-inflammatory, immune-regulating, and tumor cell growth-affecting activities .
    Linoleate sodium
  • HY-10520
    CGP 57380
    4 Publications Verification

    		 MNK Apoptosis Cancer
    CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 with IC50 of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.
    CGP 57380
  • HY-150688
    JAK3-IN-13

    		JNK Cancer
    JAK3-IN-13 (compound 12n) is a potent, selective and orally active JAK3 inhibitor with IC50 values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity .
    JAK3-IN-13
  • HY-N11536
    erythro-Austrobailignan-6

    		Topoisomerase Apoptosis Cancer
    erythro-Austrobailignan-6 is an orally active anti-cancer agent. erythro-Austrobailignan-6 inhibits DNA topoisomerase I and II activity. erythro-Austrobailignan-6 induces cell apoptosis and increases phosphorylation of p38 and JNK .
    erythro-Austrobailignan-6
  • HY-B1014
    Acenocoumarol

    		VD/VDR p38 MAPK JNK ERK NF-κB Akt GSK-3 PKA Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist. Acenocoumarol inhibits MAPK/ERK/JNK signaling pathway, reduces the nuclear translocation of NF-κB p65, activates Akt/GSK3β signaling pathway. Acenocoumarol induces apoptosis in cell A549, arrests cell cycle at S phase .
    Acenocoumarol
  • HY-162886
    BSO-07

    		JNK Reactive Oxygen Species (ROS) Cancer
    BSO-07 is a ROS/JNK activator with significant anticancer effects, having an IC50 value of 24.81 μM against human breast cancer (BC) cells. BSO-07 induces apoptosis (Apoptosis) and paraptosis by activating JNK and increasing ROS levels, including enhancing the expression of apoptosis-associated proteins such as PARP, Bax, phosphorylated p53, ATF4, and CHOP, while decreasing the levels of anti-apoptotic proteins like Bcl-2, Bcl-xL, and Survivin. BSO-07 holds promise for research in the field of breast cancer .
    BSO-07
  • HY-W762011
    BDE 47

    		Apoptosis Reactive Oxygen Species (ROS) JNK Oxidative Phosphorylation Neurological Disease Cancer
    BDE 47 targets mitochondria, inhibits mitochondrial oxidative phosphorylation (OXPHOS), decreases mitochondrial membrane potential (MMP) and induces apoptosis in embryonic cell. BDE 47 induces the generation of ROS, and activates the JNK signaling pathway. BDE 47 exhibits embryonic developmental toxicity in zebrafish .
    BDE 47
  • HY-N9866
    Grasshopper ketone

    		Others Inflammation/Immunology
    It is a bioactive compound with anti-inflammatory activity that inhibits LPS-induced NO production in RAW 264.7 cells and acts by inhibiting the phosphorylation of MAPK (ERK, JNK and p38) and NF-κB p65. Grasshopper ketone, as an ingredient, has shown its potential in anti-inflammatory inhibition .
    Grasshopper ketone
  • HY-15415
    KB-R7943 mesylate
    4 Publications Verification

    		 Na+/Ca2+ Exchanger Autophagy Cancer
    KB-R7943 mesylate is a widely used inhibitor of the reverse Na +/Ca 2+ exchanger (NCXrev) with IC50 of 5.7±2.1 μM. KB-R7943 mesylate induces cancer cell death via activating the JNK pathway and blocking autophagic flux.
    KB-R7943 mesylate
  • HY-W753791
    (±)-Perillaldehyde

    		TNF Receptor JNK Neurological Disease Inflammation/Immunology
    (±)-Perillaldehyde has an antidepressant effect by modulating the olfactory nervous system in a mouse model of stress-induced depression. (±)-Perillaldehyde also has anti-inflammatory activity, inducing JNK activation in RAW264.7 cells and inhibiting the expression of TNF-α, with an IC50 of 171.7 μM .
    (±)-Perillaldehyde
  • HY-111431A
    p-Cresyl sulfate potassium
    5 Publications Verification

    p-Tolyl sulfate potassium

    		 Endogenous Metabolite JNK p38 MAPK Metabolic Disease Inflammation/Immunology
    p-Cresyl sulfate potassium is a uremic toxin that binds to a prototype protein. p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways. p-Cresyl sulfate potassium has pro-inflammatory activity .
    p-Cresyl sulfate potassium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: